<DOC>
	<DOCNO>NCT02938741</DOCNO>
	<brief_summary>ATG base condition regimen HLA relate allogeneic hematopoietic stem cell transplantation aggressive T-cell tumor : multi-center , open , randomize control clinical study</brief_summary>
	<brief_title>ATG Based Conditioning Regimen HLA Related HSCT Aggressive T-cell Tumors</brief_title>
	<detailed_description>Aggressive T-cell lymphoma ( ATCLs ) , include peripheral T-cell lymphoma T lymphoblastoid cell lymphoma/leukemia , represent 10 % 15 % non-Hodgkin 's lymphoma ( NHLs ) adult ( 1 ) . ATCLs show bad prognosis B-cell lymphoma . Myeloablative allogeneic stem cell transplantation ( allo-SCT ) may way cure patient , recurrence primary disease transplantation still important prognostic factor ( 2 ) . Optimizing condition regimen always research hot topic hematology field . Polyclonal antithymocyte globulin ( rabbit anti-thymocyte globulin , r-ATG ) currently use prevent graft-versus -host ( GVHD ) disease allogeneic stem cell transplantation , also widely use prevention treatment acute rejection solid organ transplant strong immunomodulatory effect . ATG use allogeneic SCT prophylaxis graft versus host disease vivo T cell depletion , include complement-dependent cytotoxic response , antibody-dependent cell-mediated cytotoxicity , opsonophagocytic role phagocytic cell induce apoptosis ( 3 ) . But scholar report ATG delay immune reconstitution hematologic reconstitution lead increase incidence virus fungal infection transplantation . But often curable affect overall survival quality life patient ( 4 ) . Because strong immune suppression regulation , also basis fact , ATG GVHD prophylaxis generally limit unrelated donor , human leukocyte antigen（HLA）-mismatched related donor transplantation . But There many issue still need study . ATG show efficacy prevent acute GVHD（aGVHD ) allo-SCT , efficacy chronic GVHD ( cGVHD ) long-term outcome remain controversial . A systematic review meta-analysis Du k et al（5） report prophylactic use ATG exert favorable effect reduce cGVHD without survival impairment long term , although high relapse rate major threat . Does ATG also kill effect tumor cell lymphatic system ? The vitro study confirm point recently . Grüllich ( 6 ) et al investigator study ( 7 ) find ATG inhibit proliferation induce high level apoptosis human lymphoblastic cell line , Jurkat , Daudi , DG-75 , myeloblastic cell line K562 , HL-60 , KG1 , U937 . ATG also pro-apoptotic activity majority primary leukemia cell , particularly cell lymphatic origin . In addition , ATG result apoptosis normal hematopoietic cell . Low-dose ATG also stimulate normal hematopoietic colony growth . Therefore , ATG may use anti-lymphocyte tumor bio-therapeutics ( rituximab ) increase role chemo-radiotherapy condition regimen . And ATG remove residual tumor lesion , reduce rate tumor recurrence transplantation . The result retrospective study hospital already publish blood cancer journal . We use ATG part condition regimen evaluate long-term antileukemia effect , safety complication patient highly aggressive T-cell lymphoma . Twenty-three patient enrol study . At time transplant , six patient reach ﬁrst subsequent complete response , three patient partial remission 14 patient relapse primary refractory disease . The condition regimen consist ATG , total body irradiation , toposide cyclophosphamide . The complete remission rate transplant 95.7 % . At median follow-up time 25 month , 16 ( 69.6 % ) patient alive free disease , include nine patient refractory progressive disease . Seven patient die transplant , ﬁve relapse two treatment-related complication . The incidence grade II-IV acute graft-vs-host disease ( GvHD ) 39.1 % . The maximum cumulative incidence chronic GvHD 30 % . The frequent severe conditioning-related toxicity observe 8 23 patient grades III/IV infection cytopenia . Thus , ATG base condition feasible effective alternative patient highly aggressive T-cell tumors（8） . In view convincing result , design multi-center , open , randomize control clinical study . As noted early , high relapse rate may major threat ATG use（5）.In China , conventional dose 2.5mg/kg/day , 2-3 day Thymoglobulin commonly use GVHD prophylaxis unrelated donor , HLA-mismatched relate donor transplantation HLA match related donor transplantation ( 9 ) . In order observe anti-tumor effect condition regimen aggressive T-cell lymphoma patient ( complete remission , partial remission ) , design multi-center , open , randomize control clinical study . The donor HLA match related donor . In therapy group , add Thymoglobulin dose condition regimen four day 10mg/kg . We expect ATG base conditioning regimen play anti-tumor effect , reduce primary disease recurrence transplantation , improve disease-free survival ( DFS ) overall survival rate ( OS ) , well reduce incidence severity GVHD , incidence infection need observe . Reference:1 . Rudiger T , Weisenburger DD , Anderson JR et al . Peripheral T-cell lymphoma ( exclude anaplastic large-cell lymphoma ) : result Non-Hodgkin 's Lymphoma Classification Project . Ann Oncol 2002 ; 13:140-149 . 2 . Armitage J , Vose J , Weisenburger D. International peripheral T-cell natural killer/T-cell lymphoma study : pathology finding clinical outcome . J Clin Oncol 2008 ; 26 : 4124-4130 3 . Mohty M .Mechanisms action antithymocyte globulin : T-cell depletion beyond . Leukemia . 2007 Jul ; 21 ( 7 ) :1387-94 . Epub 2007 Apr 5 4 . Baumann H , JudithD , Zey C et al . Antithymocyte globulin Fresenius San gstat ( Genzyme ) part condition unrelated donor HSCT : emerging difference posttransplant immune reconstitution . Bone Marrow Transplant , 2004 ; 33 : S51 . 5 . Du K , Hu Y , Wu K , Huang H et al . Long-term outcome antithymocyte globulin patient hematological malignancy undergo myeloablative allogeneic hematopoietic cell transplantation : systematic review meta-analysis.Clin Transplant . 2013 Mar ; 27 ( 2 ) : E91-E100 . 6 . Grullich G , Ziegler C , Finke J et al . Rabbit Anti T-Lymphocyte Globulin Induces Apoptosis Peripheral Blood Mononuclear Cell Compartments Leukemia Cells , While Hematopoietic Stem Cells Are Apoptosis Resistant . Biol Blood Marrow Transplant , 2009 , 15:173-182 . 7 . Huixia Liu , chun wang , Youwen Qin , et al . Polyclonal Rabbit Antithymocyte Globulin induce apoptosis Cytotoxic Effects human Leukemic Cells.Clinical Lymphoma , Myeloma &amp; Leukemia 2012,12 : 345-54 8 . J Yang , C wang , Y Cai , et al.Anti-thymocyte globulin could improve outcome allogeneic hematopoietic stem cell transplantation patient highly aggressive T-cell tumors.Blood Cancer Journal ( 2015 ) 5 , e332 ; doi:10.1038/bcj.2015.54 9 . Jacobsen ED , Kim HT , Ho VT，et al . A large single-center experience allogeneic stem-cell transplantation peripheral T-cell non-Hodgkin lymphoma advance mycosis fungoides/Sezary syndrome . Annals Oncology 2011 ( 22 ) : 1608-1613</detailed_description>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<criteria>According World Health Organization ( WHO ) classification , diagnosis T cell tumor lymphatic system source ( T lymphoblastoid cell lymphoma/leukemia ) confirm pathological examination , morphology , cytochemistry , immunophenotyping chromosome examination , molecular biology include complete remission , partial remission . Performance status score 2 ( ECOG criterion ) . Adequate organ function define follow criterion : alanine transaminase （ALT） , aspartate transaminase（AST） total serum bilirubin &lt; 2×ULN ( upper limit normal ) Serum creatinine blood urea nitrogen ( BUN ) &lt; 1.25×ULN . Adequate cardiac function without acute myocardial infarction , arrhythmia atrioventricular block , heart failure , active rheumatic heart disease cardiac dilatation ( patient improve treatment disease expect affect transplant include study ) . Absence contraindication stem cell transplantation . Willingness ability perform HSCT . Signed date informed consent document indicate patient ( legally acceptable representative ) inform pertinent aspect trial prior enrollment . Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure . Presence condition inappropriate HSCT . Life expectancy &lt; 3 month severe disease . Presence fatal disease , include respiratory failure , heart failure , liver kidney function failure et al . Uncontrolled infection . Pregnancy breastfeed . Has enrol anther clinical trial Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration , may interfere interpretation study result , judgment investigator would make patient inappropriate entry study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>lymphoblastic lymphoma</keyword>
	<keyword>stem-cell transplant</keyword>
	<keyword>T-cell lymphoma</keyword>
	<keyword>ATG</keyword>
</DOC>